NASDAQ OMX

Aurora Solar Technologies Named to TSX Venture 50

Dela

Aurora Solar Technologies Inc. / Aurora Solar Technologies Named to TSX Venture 50 . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

NORTH VANCOUVER, British Columbia, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Aurora Solar Technologies Inc. ("Aurora")("Company")(TSX.V:ACU) (OTCBB:AACTF) (FSE:A82), a leader in inline measurement and control technology for the photovoltaic manufacturing industry, is pleased to announce that it has been named to the 2018 TSX Venture 50.  The Venture 50 are the top ten companies listed on TSX Venture Exchange in each of five major industry sectors - mining, energy & energy services, clean technology & life sciences, diversified industries and technology - based on a ranking formula with equal weighting given to return on investment, market cap growth, trading volume and analyst coverage. All data was as of December 31, 2017.

Michael Heaven, President, CEO, and Director of Aurora Solar Technologies, commented, "Last year was a historical year for Aurora, our employees and shareholders with the company growing five-fold in revenue for the year ending March 31, 2017 and tracking towards record revenue in the current fiscal year. 2017 was a year of volume orders from leaders in the solar industry who continue to trust us with repeat orders that help them make better solar cells.  I would like to take this opportunity to congratulate and thank all our customers, staff and investors for their continued dedication to Aurora. We are excited to celebrate this milestone and hope to deliver even more shareholder value in 2018 and beyond."

The Aurora TSX Venture 50 listing can be viewed at www.tsx.com/venture50 where you will also find an interview with Michael Heaven.

About Aurora Solar Technologies:

Aurora's mission is to deliver exceptional results to the photovoltaic industry through measurement and control of critical processes during solar cell manufacturing.

We measure and map the results of critical cell fabrication processes, providing real-time visualization of material properties and true production tool performance. Our products provide process engineers and production-line operators with the means to rapidly detect and correct process excursions, material faults, limit variations, and optimize processes, thereby eliminating yield-reducing and profit-killing product variation.

For further information contact:

Michael Heaven, P.Eng., MBA
President & Chief Executive Officer
Aurora Solar Technologies Inc.
Phone: +1 (778) 241-5000
info@aurorasolartech.com

Investor Relations contact:

Nina Lafleur
Phone: +1 (604) 679-9964
info@aurorasolartech.com

Paradox Public Relations
Phone: +1 (514) 341-0408
info@paradox-pr.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Some statements in this news release contain forward­looking information. These statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the statements. The Company does not assume the obligation to update any forward­looking statement.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Aurora Solar Technologies Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Hoylu AB: UNITED STATES ARMY SELECTS HOYLU FOR DIGITAL COLLABORATION SOLUTIONS26.9.2018 08:30Pressmeddelande

Malmo, Sweden, September 26, 2018 - Hoylu, a leading enterprise collaboration company announced today that the United States Army has selected Hoylu Software and the large format HoyluWall system as a digital workspace tool for workspace collaboration, process planning and ideation. Hoylu software will be used to modify, save, print and communicate between teams at remote locations and allow for collaborative analysis. The order will be delivered in Q3 2018 and represents a deal value of SEK 528,000 in product and software revenue and presents ongoing opportunities to expand within the government sector. This system will be installed at the Picatinny Arsenal in New Jersey, the US Army's primary R&D arm for armament and munitions systems. Picatinny Arsenal is the Joint Center of Excellence for Guns and Ammunition, providing products and services to all branches of the U.S. military. Picatinny Arsenal has partnerships with a variety of universities and industry partners, involving them i

Hoylu AB: USA:s armé väljer Hoylu för digitala samarbetslösningar26.9.2018 08:30Pressmeddelande

Malmö, Sverige, 26:e september 2018 - Hoylu, ett ledande företag inom digitala samarbetslösningar tillkännagav idag att USA:s armé har valt Hoylus mjukvara och storformats Hoylu Wall-system som verktyg för digitalt samarbete, delade arbetsytor, processplanering och idégenerering. Hoylus mjukvara kommer användas till att modifiera, spara, skriva ut och stödja samarbete mellan team på olika platser samt möjliggöra kollaborativ analys. Ordern kommer levereras under tredje kvartalet 2018 och har ett sammanlagt värde på SEK 528 000 för hård- och mjukvara. Ordern visar på ökande möjligheter att växa inom statlig och offentlig verksamhet. Systemet kommer installeras på Picatinny Arsenal i New Jersey, USA:s armés primära R&D-enhet för vapen- och ammunitionssystem. Picatinny Arsenal är ett s.k. "Joint Center of Excellence" för vapen och ammunition och de tillhandahåller produkter och tjänster åt alla grenar av USA:s armé. Picatinny Arsenal har också samarbeten med en mängd olika universitet och

Bergman & Beving AB: Aktierelaterat incitamentsprogram25.9.2018 10:00Pressmeddelande

Pressrelease Aktierelaterat incitamentsprogram Det av årsstämman 2018 beslutade aktierelaterade incitamentsprogrammet som omfattar 16 ledningspersoner om maximalt 210 000 köpoptioner på återköpta aktier av serie B har fulltecknats. Köpoptionerna kommer att överlåtas till ett pris av 7,10 SEK per köpoption vilket motsvarar marknadsvärde enligt en extern oberoende värdering utförd i enlighet med Black-Scholes-modellen. Lösenkursen för köpoptionerna uppgår till 117,90 SEK motsvarande 120 procent av den genomsnittliga aktiekursen under mätperioden 24 augusti - 7 september 2018. Varje köpoption berättigar till förvärv av en återköpt aktie av serie B under perioden från och med den 13 september 2021 till och med den 10 juni 2022. Stockholm den 25 september 2018 Bergman & Beving AB (publ) För ytterligare information kontakta: Peter Schön, CFO, telefon 070-339 89 99 Informationen lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 25 september 2018 kl. 10:00 CET. Ber

Bergman & Beving AB: Share-based incentive scheme25.9.2018 10:00Pressmeddelande

Press Release Share-based incentive scheme The share-based incentive scheme resolved by the 2018 Annual General Meeting where 16 members of senior management were offered to acquire up to 210,000 call options on repurchased class B shares has been fully subscribed. The call options will be transferred at a price of SEK 7.10 per call option, equivalent to the market value according to an external independent valuation, applying the Black-Scholes-model. The redemption price of the call options amounts to SEK 117.90, equivalent to 120 percent of the volume-weighted average of the paid market price for the shares during the period from 24 August to 7 September 2018, inclusive. Each call option entitles the holder to acquire one repurchased class B share during the period from 13 September 2021 to 10 June 2022, inclusive. Stockholm den 25 September 2018 Bergman & Beving AB (publ) Contact information Peter Schön, CFO, Bergman & Beving AB, Tel: +46 70 339 89 99 The information was submitted f

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum